Confluence Wealth Services Inc. Raises Stock Position in Johnson & Johnson $JNJ

Key Points

• Confluence Wealth Services increased its Johnson & Johnson position by 17.2% in the second quarter, bringing its holdings to 49,349 shares valued at approximately $12.5 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded quarterly earnings and revenue estimates, reporting $2.90 in EPS and $25.31 billion in revenue, while maintaining 2026 EPS guidance of $11.60–$11.75. Analysts have a consensus “Moderate Buy” rating with an average price target of $268.22.
• The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.1% yield, while insiders have sold nearly 49,000 shares worth about $12.3 million over the past 90 days.

Confluence Wealth Services Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 17.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 49,349 shares of the company's stock after buying an additional 7,238 shares during the period. Confluence Wealth Services Inc.'s holdings in Johnson & Johnson were worth $12,533,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Sierra Capital LLC increased its stake in Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company's stock worth $1,685,000 after acquiring an additional 41 shares during the last quarter. Beaird Harris Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 1.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock valued at $501,000 after purchasing an additional 42 shares during the last quarter. Ballast Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.2% in the 1st quarter. Ballast Advisors LLC now owns 3,598 shares of the company's stock valued at $879,000 after purchasing an additional 42 shares during the last quarter. Crown Wealth Group LLC boosted its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Crown Wealth Group LLC now owns 2,736 shares of the company's stock worth $695,000 after purchasing an additional 42 shares during the period. Finally, Broadleaf Partners LLC increased its position in shares of Johnson & Johnson by 0.6% during the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company's stock valued at $1,521,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ opened at $260.44 on Monday. The company has a market capitalization of $627.63 billion, a price-to-earnings ratio of 30.18, a PEG ratio of 2.48 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $274.90. The business's fifty day simple moving average is $251.92 and its 200-day simple moving average is $241.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same period in the prior year, the firm earned $2.77 earnings per share. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on JNJ. TD Cowen increased their price target on Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a report on Monday, July 13th. Scotiabank reaffirmed an "outperform" rating and set a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Citigroup boosted their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Finally, Morgan Stanley raised their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $268.22.

Insider Activity

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the company's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 48,972 shares of company stock worth $12,295,205. Corporate insiders own 0.16% of the company's stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Constructive post-earnings outlook: JNJ’s latest results exceeded analyst expectations for both earnings and revenue, while full-year 2026 EPS guidance remains centered around $11.60-$11.75. Analysts are watching for continued estimate increases and earnings momentum to support the stock’s advance. Why Is Johnson & Johnson Up Since Its Last Earnings Report?
• Positive Sentiment: Pharmaceutical recovery and defensive appeal: JNJ is among the large-cap pharmaceutical companies investors are watching as the industry recovery gains traction. Its diversified healthcare business and relatively low-beta profile may also attract investors seeking defensive exposure amid market uncertainty. Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
• Positive Sentiment: Dividend record reinforces income appeal: JNJ raised its dividend 3.1% to $5.36 per share annually, extending its streak of consecutive increases to 64 years. The increase supports the company’s reputation as a long-term income and stability investment. Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years
• Neutral Sentiment: Talc settlement remains a key overhang: Analysis of JNJ’s proposed $5.5 billion talc settlement views it as a potential step toward reducing litigation uncertainty, but the long-term financial and legal impact remains subject to scrutiny. Johnson & Johnson’s $5.5B Talc Settlement
• Neutral Sentiment: Portfolio adjustments: JNJ sold its remaining rights and interests in botaretigene sparoparvovec to MeiraGTx for $25 million. The transaction may streamline the portfolio, but its financial contribution is unlikely to materially affect near-term results. MeiraGTx Reports Second Quarter 2026 Results
• Negative Sentiment: Robotics competition is increasing: Intuitive Surgical cited growing competitive pressure from JNJ and Chinese robotic-surgery platforms. While this reflects JNJ’s ambitions in surgical robotics, it also signals that gaining market share could require substantial investment and execution. Intuitive Surgical Beats on Q2 Results

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source